29
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      To submit your manuscript, please click here

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Oral contraceptives (OCs) have been used as a first-line option for medical treatment in women with polycystic ovary syndrome (PCOS). Despite theoretical superiority of products containing antiandrogenic progestins compared to OCs containing levonorgestrel (LNG), the clinical advantage of these compounds remains unclear.

          Objective

          The aim of this study was to compare the effects of OCs containing LNG with products containing antiandrogenic progestins including cyproterone acetate, drospirenone, and desogestrel on clinical, hormonal, and metabolic parameters and quality of life in women with PCOS.

          Methods

          We conducted a 6-arm crossover randomized controlled trial with each arm including OCs containing LNG and one of those 3 OCs containing antiandrogenic progestins. The anthropometric and clinical manifestations and hormonal and biochemical parameters of participants were assessed at 6 time points including baseline, after washout period, and 3 and 6 months after intervention.

          Results

          The study is ongoing and follow-up of recruited women will continue until 2018.

          Conclusions

          This study will provide scientific evidence on comparability of OCs with the various progesterones that will assist in decision making taking into account cost effectiveness.

          Trial Registration

          Iranian Registry of Clinical Trials IRCT201702071281N2; http://www.irct.ir/searchresult.php? keyword=&id=1281&number=2&prt=12869&total=10&m=1 (Archived by WebCite at http://www.webcitation.org/6tSP8FNWo)

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Polycystic Ovary Syndrome

          New England Journal of Medicine, 352(12), 1223-1236
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.

            Androgenetic alopecia in the female occurs much more frequently than is generally believed. The condition is still considered infrequent, for it differs, in its clinical picture and in the sequence of events leading to it, from common baldness in men. To facilitate an early diagnosis (desirable in view of the therapeutic possibilities by means of antiandrogens) a classification of the stages of the common form (female type) of androgenetic alopecia in women is presented. The exceptionally observed male type of androgenetic alopecia can be classified according to Hamilton or to the modification of this classification proposed by Ebling & Rook.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome.

              Polycystic ovary syndrome (PCOS) has been shown to cause a reduction in quality of life. This study examines the extent of different PCOS symptoms on quality-of-life, psychosocial well-being and sexual satisfaction. Complete metabolic, hormonal, clinical and psychosocial data were obtained from a total of 120 women with PCOS. Patients were compared with 50 healthy women to establish reductions in quality-of-life and emotional well-being. In addition, the correlation between psychosocial variables and the major clinical PCOS features obesity (body mass index (BMI)), excessive body hair (hirsutism score), acne, hyperandrogenism (serum testosterone levels), disturbed insulin regulation (area under the insulin response curve and homeostasis model assessment of insulin resistance), menstrual cycle disturbances and infertility were analyzed. PCOS patients showed significant reductions in quality-of-life, increased psychological disturbances, and decreased sexual satisfaction when compared with healthy controls. BMI and hirsutism scores, but not the presence of acne, were associated with physical aspects of quality-of-life and sexual satisfaction. No clear effect of androgens or insulin resistance on psychosocial variables was detected. Similarly, the type of menstrual cycle disturbances or infertility had no impact on psychological well-being. In PCOS, changes in appearance, particularly obesity and hirsutism, reduce physical dimensions of quality-of-life and decrease sexual satisfaction. The role of biochemical, endocrine and metabolic parameters as well as menstrual irregularities and infertility appeared to be less important. Clinicians should pay attention to the psychosocial dimensions of PCOS on an individual basis, regardless of symptom severity or treatment response.
                Bookmark

                Author and article information

                Contributors
                Journal
                JMIR Res Protoc
                JMIR Res Protoc
                ResProt
                JMIR Research Protocols
                JMIR Publications (Toronto, Canada )
                1929-0748
                September 2017
                29 September 2017
                : 6
                : 9
                : e191
                Affiliations
                [1] 1 Department of Midwifery and Reproductive Health Faculty of Nursing and Midwifery Shahid Beheshti University of Medical Sciences Tehran Islamic Republic Of Iran
                [2] 2 Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences Tehran Islamic Republic Of Iran
                [3] 3 Prevention of Metabolic Disorders Research Center Research Institute for Endocrine Science Shahid Beheshti University of Medical Sciences Tehran Islamic Republic Of Iran
                [4] 4 Department of Epidemiology and Biostatistics School of Public Health Tehran University of Medical Sciences Tehran Islamic Republic Of Iran
                Author notes
                Corresponding Author: Fahimeh Ramezani Tehrani ramezani@ 123456endocrine.ac.ir
                Author information
                http://orcid.org/0000-0002-1126-9297
                http://orcid.org/0000-0002-0837-3683
                http://orcid.org/0000-0003-4956-1039
                http://orcid.org/0000-0002-2533-167X
                http://orcid.org/0000-0002-4609-065X
                Article
                v6i9e191
                10.2196/resprot.8631
                5640820
                28963092
                ed7976a4-b72c-4c26-b668-9570e29fef05
                ©Mina Amiri, Fatemeh Nahidi, Davood Khalili, Razieh Bidhendi-Yarandi, Fahimeh Ramezani Tehrani. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 29.09.2017.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.

                History
                : 2 August 2017
                : 23 August 2017
                : 27 August 2017
                : 28 August 2017
                Categories
                Protocol
                Protocol

                polycystic ovary syndrome,oral contraceptives,randomized controlled trial,progestin

                Comments

                Comment on this article